Key trends include strategic CDMO partnerships and a shift to in vivo administration, enhancing accessibility and innovation ...
CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
PARIS, France (September 12, 2024) - Genethon, the pioneering French laboratory and leader in the research and development of gene therapies for rare diseases, announced today publication in Nature ...
A gene therapy that aims to increase levels of two key proteins that enable the growth of new blood vessels in age-related macular degeneration (AMD) was shown to stabilize vision with a low rate of ...
Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...
Diseases that affect the retina, the light-sensitive layer at the back of the eye, are a significant cause of visual impairment and blindness. Gene therapy holds promise for treating some of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results